{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Triple-negative+Breast+Carcinoma&page=3",
    "query": {
      "condition": "Triple-negative Breast Carcinoma",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 761,
    "total_pages": 77,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Triple-negative+Breast+Carcinoma&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Triple-negative+Breast+Carcinoma&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-09T09:26:14.727Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01676753",
      "title": "Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced or Metastatic Breast Cancer",
        "Triple Negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Dinaciclib",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jo Chien",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 32,
      "start_date": "2016-12-28",
      "completion_date": "2022-02-28",
      "has_results": false,
      "last_update_posted_date": "2022-09-21",
      "last_synced_at": "2026-10-09T09:26:14.727Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01676753"
    },
    {
      "nct_id": "NCT02554812",
      "title": "A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Cancer"
      ],
      "interventions": [
        {
          "name": "Avelumab",
          "type": "DRUG"
        },
        {
          "name": "Utomilumab",
          "type": "DRUG"
        },
        {
          "name": "PF-04518600",
          "type": "DRUG"
        },
        {
          "name": "PD 0360324",
          "type": "DRUG"
        },
        {
          "name": "CMP-001",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 409,
      "start_date": "2015-11-09",
      "completion_date": "2023-03-23",
      "has_results": true,
      "last_update_posted_date": "2024-07-30",
      "last_synced_at": "2026-10-09T09:26:14.727Z",
      "location_count": 57,
      "location_summary": "Encinitas, California • La Jolla, California • Los Angeles, California + 23 more",
      "locations": [
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02554812"
    },
    {
      "nct_id": "NCT02744053",
      "title": "DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients With Triple Negative Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Estrogen Receptor Negative",
        "HER2/Neu Negative",
        "Progesterone Receptor Negative",
        "Triple-Negative Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Dynamic Contrast-Enhanced Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Scintimammography",
          "type": "RADIATION"
        },
        {
          "name": "Technetium Tc-99m Sestamibi",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER",
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 96,
      "start_date": "2016-11-07",
      "completion_date": "2028-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-07",
      "last_synced_at": "2026-10-09T09:26:14.727Z",
      "location_count": 6,
      "location_summary": "Houston, Texas • Nassau Bay, Texas • Sugar Land, Texas + 1 more",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Nassau Bay",
          "state": "Texas"
        },
        {
          "city": "Sugar Land",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02744053"
    },
    {
      "nct_id": "NCT02260531",
      "title": "Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Brain Tumor - Metastatic"
      ],
      "interventions": [
        {
          "name": "Cabozantinib",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2014-11",
      "completion_date": "2020-03-17",
      "has_results": true,
      "last_update_posted_date": "2021-05-20",
      "last_synced_at": "2026-10-09T09:26:14.727Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02260531"
    },
    {
      "nct_id": "NCT03225547",
      "title": "Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Triple Negative Breast Neoplasms",
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Mifepristone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2018-02-12",
      "completion_date": "2025-09-30",
      "has_results": false,
      "last_update_posted_date": "2025-12-23",
      "last_synced_at": "2026-10-09T09:26:14.727Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03225547"
    },
    {
      "nct_id": "NCT03639948",
      "title": "Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Triple-negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Pegfilgrastim",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Kansas Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 70 Years · Female only"
      },
      "enrollment_count": 120,
      "start_date": "2018-09-04",
      "completion_date": "2024-11",
      "has_results": true,
      "last_update_posted_date": "2024-04-11",
      "last_synced_at": "2026-10-09T09:26:14.727Z",
      "location_count": 9,
      "location_summary": "Fairway, Kansas • Kansas City, Kansas • Overland Park, Kansas + 4 more",
      "locations": [
        {
          "city": "Fairway",
          "state": "Kansas"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03639948"
    },
    {
      "nct_id": "NCT01818999",
      "title": "Ixabepilone and SBRT For Metastatic Breast Cancer",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "METASTATIC BREAST CANCER"
      ],
      "interventions": [
        {
          "name": "IXABEPILONE",
          "type": "DRUG"
        },
        {
          "name": "STEREOTACTIC BODY RADIATION THERAPY",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 99 Years · Female only"
      },
      "enrollment_count": 0,
      "start_date": "2013-08",
      "completion_date": "2015-04",
      "has_results": false,
      "last_update_posted_date": "2020-08-20",
      "last_synced_at": "2026-10-09T09:26:14.727Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01818999"
    },
    {
      "nct_id": "NCT06885424",
      "title": "A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Solid Tumor Cancer",
        "Solid Tumor, Unspecified, Adult",
        "Colorectal Carcinoma",
        "Colorectal Carcinoma (CRC)",
        "Non Small Cell Lung Cancer",
        "Small Cell Lung Cancer ( SCLC )",
        "Pancreatic Cancer",
        "NSCLC",
        "Mesothelioma",
        "Ovarian Cancer",
        "Ovarian Carcinoma",
        "Head and Neck (HNSCC)",
        "Head and Neck Cancer",
        "Renal Cell Carcinoma (Kidney Cancer)",
        "Triple Negative Breast Cancer (TNBC)"
      ],
      "interventions": [
        {
          "name": "No additional intervention administered in this long term follow-up study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "A2 Biotherapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 400,
      "start_date": "2025-07-31",
      "completion_date": "2040-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-20",
      "last_synced_at": "2026-10-09T09:26:14.727Z",
      "location_count": 3,
      "location_summary": "Gilbert, Arizona • Rochester, Minnesota • New York, New York",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06885424"
    },
    {
      "nct_id": "NCT00674206",
      "title": "A Phase II Trial of Gemcitabine and Oxaliplatin for Triple Negative Metastatic Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2008-10",
      "completion_date": "2009-10",
      "has_results": true,
      "last_update_posted_date": "2013-12-12",
      "last_synced_at": "2026-10-09T09:26:14.727Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00674206"
    },
    {
      "nct_id": "NCT03449108",
      "title": "LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bone Sarcoma",
        "Dedifferentiated Chondrosarcoma",
        "Giant Cell Tumor of Bone",
        "Malignancy in Giant Cell Tumor of Bone",
        "Malignant Solid Neoplasm",
        "Ovarian Carcinosarcoma",
        "Platinum-Resistant Ovarian Carcinoma",
        "Poorly Differentiated Thyroid Gland Carcinoma",
        "Recurrent Osteosarcoma",
        "Recurrent Ovarian Carcinoma",
        "Refractory Osteosarcoma",
        "Soft Tissue Sarcoma",
        "Thyroid Gland Anaplastic Carcinoma",
        "Thyroid Gland Squamous Cell Carcinoma",
        "Undifferentiated High Grade Pleomorphic Sarcoma of Bone",
        "Triple Negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Aldesleukin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Autologous Tumor Infiltrating Lymphocytes LN-145",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Autologous Tumor Infiltrating Lymphocytes LN-145-S1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "16 Years to 70 Years"
      },
      "enrollment_count": 30,
      "start_date": "2018-04-27",
      "completion_date": "2027-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-05-22",
      "last_synced_at": "2026-10-09T09:26:14.727Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03449108"
    }
  ]
}